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Background: This study investigated the impact of renal dysfunction (RD) on long-term outcomes in elderly
patients with acute coronary syndrome (ACS), and evaluated prognostic factors in elderly patients with ACS and RD.
Methods: This longitudinal prospective study included 184 consecutive patients who were admitted with ACS
between January 2009 and January 2010 and also had RD. Patients were divided into five groups according to their
estimated glomerular filtration rate (eGFR): 1) eGFR ≥ 90 mL/min/1.73 m2 with evidence of kidney damage, 2) 60 ≤
eGFR < 90 mL/min/1.73 m2, 3) 30 ≤ eGFR < 60 mL/min/1.73 m2, 4) 15 ≤ eGFR < 30 mL/min/1.73 m2, and 5) eGFR <
15 mL/min/1.73 m2. The primary endpoints were death and complications during hospitalization. The secondary
endpoint was any major adverse cardiac event (MACE) during follow-up.
Results: The mean follow-up period was 502.2 ± 203.6 days. The mean patient age was 73.7 ± 9.4 years, and 61.4%
of the patients were men. Severe RD (eGFR < 30 mL/min/1.73 m2) was an independent predictor of MACE. Severe
RD was associated with a low hemoglobin level, low left ventricular ejection fraction, and high levels of high-
sensitivity C-reactive protein, N-terminal pro-B-type natriuretic peptide, and cystatin C. Survival was significantly
poorer in patients with severe RD than in patients with mild RD.
Conclusions: Among patients with ACS, severe RD was associated with advanced age, diabetes, hypertension, and
cardiac dysfunction. Severe RD was an independent risk factor for MACE, and was associated with poor prognosis.
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Morbidity associated with chronic kidney disease (CKD)
has increased with the growth of aging populations.
CKD is strongly associated with increased mortality rate
and accelerated cardiovascular disease (CVD) [1]. Pa-
tients with CKD have complex clinical conditions and a
poor prognosis, and are difficult to treat [2-4]. One of
the main concerns for patients with CKD is the in-
creased risk of CVD, including coronary heart disease,* Correspondence: ametuofo980869@163.com; liyangbsh@163.com
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[5-10]. A meta-analysis found that individuals with renal
insufficiency have an approximately 3-fold increased risk
of CVD mortality compared with their counterparts
without renal insufficiency [5]. Despite strong evidence
linking CKD to poor outcomes, the impact of CKD on
mortality and morbidity in elderly patients with acute
coronary syndrome (ACS) is probably underappreciated,
and elderly patients with CKD may not be treated as ag-
gressively as patients with normal renal function. This
study evaluated the impact of renal dysfunction (RD) on
clinical outcomes including death, complications, and
major adverse cardiac events (MACEs) in elderly pa-
tients with ACS.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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Study population
We analyzed the data of 184 consecutive elderly patients
(all older than 60 years, mean age 73.7 ± 9.4 years, 61.4%
men) who were admitted to our department with ACS
between January 2009 and January 2010. All patients
were discharged with a diagnosis of ACS based on car-
diac enzyme levels and electrocardiography findings.
Coronary angiography was performed in 129 patients.
The secondary endpoint was analyzed in 147 patients,
excluding 18 patients who were transferred to other hos-
pitals or died, and 19 patients who were lost to follow-
up. The ethics committee of the Chinese PLA General
Hospital approved this study, and written informed con-
sent for inclusion in the study was obtained from all
subjects.
Definitions
The abbreviated Modification of Diet in Renal Disease
formula was used to calculate the estimated glomerular
filtration rate (eGFR) from the serum creatinine level
[11]. Patients were divided into five groups according to
their eGFR: Group I, eGFR ≥ 90 mL/min/1.73 m2 (n =
13, age 63.3 ± 5.1 years, 61.5% men); Group II, 60 ≤
eGFR < 90 mL/min/1.73 m2 (n = 15, age 65.2 ± 7.4 years,
73.3% men); Group III, 30 ≤ eGFR < 60 mL/min/1.73 m2
(n = 81, age 76.0 ± 7.6 years, 69.2% men); Group IV, 15 ≤
eGFR < 30 mL/min/1.73 m2 (n = 45, age 74.3 ± 8.7 years,
53.3% men); and Group V, eGFR ≤ 15 mL/min/1.73 m2
(n = 30, age 75.2 ± 12.9 years, 60% men).
Acute kidney injury is defined as a rapid reduction in
renal function characterized by progressive azotemia
(determined by the serum creatinine level), with or with-
out oliguria. Acute kidney injury is categorized as Stage
1 if there is an increase in the serum creatinine level of
50% or ≥ 0.3 mg/dL within 48 h, Stage 2 if there is an in-
crease in the serum creatinine level of ≥ 100% (doubling),
or Stage 3 if there is an increase in the serum creatinine
level of ≥ 200% or of 0.5 mg/dL to at least 4.0 mg/dL.
The primary endpoints were death and complications
during hospitalization. The secondary endpoint was any
MACE during the follow-up period, including cardiac
death, myocardial infarction, stroke, and emergency or
elective repeat revascularization. Cardiac death was de-
fined as mortality not resulting from noncardiac disease.
The infarct-related artery was defined according to the
American College of Cardiology/American Heart Associ-
ation classification and the Thrombolysis In Myocardial
Infarction flow grade [12]. Target lesion revascularization
was defined as repeat revascularization with stenosis of
≥ 50% in the treated lesion. Target vessel revascularization
was defined as repeat revascularization of the treated ves-
sel. MACE was defined as any of cardiac death, myocar-
dial infarction, target lesion revascularization, or targetvessel revascularization. Other major bleeding was defined
as severe bleeding other than intracranial bleeding. Death
and complications during hospitalization were recorded,
including cardiogenic shock, ventricular tachycardia or
fibrillation requiring anti-arrhythmic drugs or defibrilla-
tion, atrioventricular block requiring temporary cardiac
pacemaker insertion, recurrent myocardial ischemia or in-
farction, stroke, major bleeding, and acute kidney injury. If
more than two complications occurred in a single patient,
each complication type was recorded. After discharge, any
MACEs during the follow-up period were recorded.
Clinical data collection
Laboratory data were collected on admission, including
the levels of total cholesterol, low-density lipoprotein,
hemoglobin, high-sensitivity C-reactive protein (hs-CRP),
N-terminal pro-B-type natriuretic peptide (NT-proBNP),
serum creatinine, troponin-T, creatine kinase-MB, and
cystatin C (Cys C). Echocardiographic parameters were
assessed by transthoracic echocardiography using the
Teichholz method before coronary angiography, including
thickness of the interventricular septum, left ventricular
end-diastolic inner volume, left ventricular posterior wall
thickness, and left ventricular ejection fraction.
Statistical analysis
Statistical analyses were performed using the Statistical
Package for Social Sciences software (SPSS version 13.0).
Continuous variables with normal distributions were
expressed as mean ± standard deviation and compared
using 1-way analysis of variance. Categorical variables
were compared using the chi-square test where appropri-
ate. MACE was estimated by the unadjusted Kaplan–
Meier method in the five eGFR groups. Cox proportional
hazards modeling was used to examine the relationships
between survival and a prespecified list of risk factors for
MACE, including kidney function. The analyses were ad-
justed for hypertension, diabetes mellitus, smoking, sex,
hyperlipidemia, age, hemoglobin level, surgical interven-
tions, and medications (including aspirin, beta-blockers,
angiotensin-converting enzyme inhibitors, calcium chan-
nel blockers, and statins).
Results
Baseline characteristics
A total of 184 patients were included in this study, in-
cluding 13 (7.1%) with ST-segment elevation myocardial
infarction, 48 (26.1%) with non-ST-segment elevation
myocardial infarction, and 123 (66.8%) with unstable an-
gina. The median follow-up period was 502.2 ± 203.6 days.
The mean patient age was 73.7 ± 9.4 years, and 61.4% of
the patients were men. Patients with severe RD (eGFR <
30 mL/min/1.73 m2) had higher rates of comorbid
conditions than those without severe RD, including
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64.0%), current smoking (n = 25, 33.3%), hyperlipidemia
(n = 15, 20.0%), and a history of ischemic heart disease
(n = 44, 58.6%). More severe RD was significantly associ-
ated with older age, hypertension, hyperlipidemia, ische-
mic heart disease, and high Killip class (p < 0.05) (Table 1).
Biochemical parameters and echocardiography findings
Table 2 shows the baseline continuous variables. More
severe RD was associated with a lower hemoglobin level,
lower left ventricular ejection fraction, and higher levels
of hs-CRP, NT-proBNP, and Cys C. The thickness of the
interventricular septum, left ventricular end-diastolic
inner volume, and left ventricular posterior wall thick-
ness were greater in patients with severe RD than in pa-
tients with mild RD.
Coronary angiography results
Table 3 shows the coronary angiography data with differ-
ent groups eGFR groups. A total of 129 (70.1%) patients
underwent coronary angiography. The number of in-
volved vessels did not differ among the groups; patients
with severe RD had more complex lesions in the left
main coronary artery and in the infarct-related artery
compared with the mild renal dysfunction group.
Risk factors and outcomes
Table 4 shows the in-hospital and out-of-hospital out-
comes according to eGFR groups. In patients withTable 1 Baseline characteristics
Group I N = 13 Group II N = 15 Group
Age (yrs) 63.3 ± 5.1 65.2 ± 7.4 76.0 ±
Male (%) 8 (61.5) 11 (73.3) 48 (69.
BMI (kg/m2) 25.9 ± 1.7 27.3 ± 5.2 25.6 ±
Risk factor (%)
Hypertension 3 (23.1) 12 (80.0) 51 (62.
DM 8 (61.5) 9 (60.0) 27 (33.
Smoking 3 (23.1) 5 (33.3) 19 (23.
Hyperlipidemia 8 (61.5) 9 (60.0) 18 (22.
IHD 3 (23.1) 7 (46.7) 30 (37.
Symptom at admission (%)
Chest pain 8 (61.5) 10 (66/7) 39 (50.
Dyspnea 0 (0.0) 1 (6.7) 5 (6.4)
Killip class 1.67 ± 1.1 1.67 ± 1.2 2.3 ± 1
Diagnosis
UA 8 (61.5) 11 (73.3) 54 (6.7
NSTEMI 5 (38.5) 2 (13.3) 23 (28.
STEMI 0 (0) 2 (13.3) 4 (4.9)
DM, diabetes mellitus; IHD, ischemic heart disease; STEMI, ST-segment elevation my
angina; NS, not significant.normal renal function, the estimated in-hospital death
rate was 0% and the estimated in-hospital complication
rate was 7.7%. Major bleeding occurred in one patient,
who was in Group I. Cardiogenic shock occurred in five
patients. Atrioventricular block occurred in four patients
and ventricular tachycardia occurred in four patients,
who were all in Group V. In patients with moderate RD,
the in-hospital death rate (3.9%) and the in-hospital
complication rate (20.6%) were significantly higher than
in Group I (both p < 0.05). The incidence of MACE
during follow-up was higher in Group V than in Group I
(p < 0.05). Figure 1 shows the Kaplan–Meier analyses for
MACE-free survival during follow-up according to eGFR
groups. Patients with severe RD had a lower probability of
event-free survival than patients in the other groups. Cox
multivariate regression analysis showed that eGFR was the
main independent predictor of MACE (odds ratio 0.953,
95% confidence interval 0.926–0.982, p = 0.0004).
Cox regression analysis of risk factors including eGFR
showed that severe RD was an independent risk factor
for MACE in patients with ACS, and was associated with
poor prognosis. Anemia and statin drugs were also sig-
nificantly associated with prognosis (p < 0.05, Table 5).
Discussion
The results of recent studies of the relationships be-
tween CKD and mortality and morbidity after ACS sug-
gest that severe RD is an independent predictor of
cardiovascular events [13-15]. RD is directly or indirectlyIII N = 81 Group IV N = 45 Group V N = 30 P
7.6 74.2 ± 8.7 75.2 ± 12.9 0.000
2) 24 (53.3) 18 (60.0) NS
1.6 23.8 ± 2.9 23.9 ± 2.1 0.000
9) 21 (46.7) 27 (90.0) 0.001
3) 15 (33.3) 15 (50.0) NS
5) 17 (37.7) 8 (26.7) NS
2) 6 (13.3) 9 (30.0) 0.0003
0) 22 (48.9) 22 (73.3) 0.005
0) 29 (64.4) 21 (70.0) NS
3 (6.7) 2 (6.7) NS
.2 2.5 ± 1.1 3.3 ± 0.5 0.000
NS
) 27 (60.0) 21 (70.0) NS
4) 15 (33.3) 6 (20.0) NS
3 (6.7) 3 (10.0) NS
ocardial infarction; NSTEMI, non-ST-segment myocardial infarction; UA, unstable
Table 2 Biochemical parameters and echocardiogram findings
Group I N = 13 Group II N = 15 Group III N = 81 Group IV N = 45 Group V N = 30 P
GFR (mL/min) 106.8 ± 9.2 69.2 ± 6.1 42.9 ± 9.4 24.7 ± 7.5 10.9 ± 3.4 0.013
Creatinine (mg/dL) 64.1 ± 20.1 103.0 ± 19.4 126.6 ± 40.5 331.4 ± 148.4 497.3 ± 377.9 0.003
Troponin T (ng/mL) 0.12 ± 0.10 0.09 ± 0.04 0.41 ± 0.33 0.21 ± 0.09 0.59 ± 0.49 0.918
CK-MB (U/L) 7.3 ± 2.9 9.9 ± 3.6 13.1 ± 4.6 13.2 ± 3.7 17.2 ± 9.7 0.627
Hgb (g/dL) 123.1 ± 12.1 135.8 ± 13.9 127.6 ± 18.2 107.1 ± 23.7 93.2 ± 22.9 0.000
TC (mmol/L) 3.6 ± 1.2 5.3 ± 1.6 4.3 ± 1.1 4.4 ± 1.6 3.4 ± 0.9 0.159
LDL-C (mmol/L) 2.3 ± 0.9 2.9 ± 1.2 2.4 ± 0.7 2.5 ± 1.3 1.8 ± 0.6 0.257
hs-CRP (mg/dL) 0.6 ± 0.5 1.1 ± 0.7 1.7 ± 0.9 2.7 ± 1.2 4.9 ± 3.7 0.000
Cys C (mg/l) 0.6 ± 0.3 1.0 ± 0.4 1.4 ± 0.5 2.4 ± 1.2 3.7 ± 2.8 0.000
NT-proBNP (pg/mL) 307.6 ± 52.4 1013.8 ± 639.5 4305.5 ± 1054.5 9687.3 ± 3014.7 10636.8 ± 4016.9 0.000
LVEF (%) 62 ± 13 53 ± 13 48 ± 11 49 ± 10 46 ± 12 0.007
IVS (mm) 9.3 ± 1.5 10.8 ± 1.8 11.2 ± 1.3 11.9 ± 1.4 12.2 ± 1.8 0.021
LVPWT (mm) 9.3 ± 1.4 11.4 ± 2.3 10.6 ± 1.2 11.2 ± 1.7 12.0 ± 1.1 0.028
EDV (ml) 48.0 ± 3.0 48.8 ± 6.2 49.4 ± 5.9 50.5 ± 6.8 56.2 ± 5.6 0.046
GFR, glomerular filtration rate; Hgb, hemoglobin; TC, total cholesterol; LDL, low-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; NT-proBNP, N-terminal
pro-B-type natriuretic peptide; CK-MB, creatine kinase-MB; NS, not significant; Cys C, cystatin C; LVEF, left ventricular ejection fraction; IVS, interventricular septal
thickness; LVPWT, left ventricular posterior wall thickness; EDV, left ventricular end-diastolic inner volume.
Table 3 Baseline coronary angiographic findings
Group I N = 13 Group II N = 15 Group III N = 81 Group IV N = 45 Group V N = 30 P
CAG (%) 13 (100) 15 (100) 63 (77.8) 23 (51.1) 15 (50) 0.000
Infarct-related artery (%)
LAD 8 (61.5) 10 (66.7) 41 (65.1) 11 (47.8) 7 (46.7) 0.001
LCx 1 (7.7) 1 (6.7) 7 (11.1) 3 (13.0) 1 (6.7) NS
RCA 4 (30.8) 3 (20.0) 13 (20.6) 7 (30.4) 4 (26.7) NS
LM 0 (0) 1 (6.7) 2 (3.2) 2 (8.7) 3 (20.0) NS
Involved vessel number (%)
1 Branch 7 (53.8) 8 (53.3) 23 (36.5) 11 (47.8) 5 (33.3) NS
2 branch 4 (30.8) 4 (26.7) 32 (50.8) 7 (30.4) 3 (20.0) NS
3 branch 2 (15.4) 2 (13.3) 7 (11.1) 2 (8.7) 4 (26.7) NS
LM, isolated 0 (0) 1 (6.7) 1 (1.6) 1 (4.3) 1 (6.7) NS
LM, complex 0 (0) 0 (0) 0 (0) 2 (8.7) 2 (13.3) 0.032
ACC / AHA classification
A 7 (53.8) 5 (33.3) 21 (33.3) 2 (8.7) 3 (20.0) 0.045
B1 4 (30.8) 6 (40.0) 22 (34.9) 8 (34.8) 2 (13.3) NS
B2 2 (15.4) 3 (20.0) 13 (20.6) 7 (30.4) 4 (26.7) NS
C 0 (0) 1 (6.7) 7 (11.1) 6 (26.1) 6 (40.0) 0.011
TIMI flow (%)
TIMI 0 0 (0) 3 (20.0) 4 (6.3) 4 (17.4) 3 (20.0) NS
TIMI 1 1 (7.7) 1 (6.7) 2 (3.2) 2 (8.7) 1 (6.7) NS
TIMI 2 3 (23.1) 1 (6.7) 13 (20.6) 2 (8.7) 1 (6.7) NS
TIMI 3 9 (69.2) 10 (66.7) 44 (69.8) 15 (65.2) 10 (66.7) NS
LM, left main; ACC/AHA, American College of Cardiology/American Heart Association; TIMI, thrombolysis in myocardial infarction; NS, not significant.
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Table 4 Outcomes according to estimated glomerular filtration rate
Group I N = 13 Group II N = 15 Group III N = 81 Group IV N = 45 Group V N = 30 P
In-hospital outcome
Death (%) 0 1 (6.7) 4 (4.9) 2 (4.4) 6 (20) 0.046
Complications (%) 1 (7.7) 1 (6.7) 5 (6.7) 4 (8.8) 8 (26.7) 0.031
AKI 0 1 (6.7) 2 (2.5) 1 (2.2) 2 (6.7) NS
Cardiogenic shock 0 1 (6.7) 2 (2.5) 4 (8.8) 5 (16.7) NS
Major bleeding 1 (7.7) 0 1 (1.2) 1 (2.2) 1 (3.3) NS
AV block 0 0 1 (1.2) 2 (4.4) 4 (13.3) 0.039
VT 0 0 1 (1.2) 2 (4.4) 4 (13.3) 0.039
Hospital stay (days) 10.3 ± 10.9 19.8 ± 11.9 19.9 ± 18.8 24.5 ± 28.1 29.1 ± 12.5 0.042
Out-hospital outcome
MACE (%) 1 (7.7) 2 (13.3) 7 (8.6) 5 (11.1) 10 (33.3) 0.015
Cardiac death 0 0 1 (1.2) 2 (4.4) 2 (6.7) NS
MI 0 1 (6.7) 1 (1.2) 2 (4.4) 5 (16.7) 0.016
Re-PCI 1 (7.7) 2 (26.7) 3 (3.7) 4 (8.9) 4 (13.3) NS
TVR 1 (7.7) 2 (13.3) 1 (1.2) 2 (4.4) 2 (6.7) NS
Non-TVR 0 1 (6.7) 1 (1.2) 1 (2.2) 1 (3.3) NS
TLR 0 1 (6.7) 1 (1.2) 1 (2.2) 1 (3.3) NS
CABG 0 1 (6.7) 0 () 1 (2.2) 1 (3.3) NS
Stroke 1 (7.7) 0 0 1 (2.2) 2 (6.7) NS
AKI, acute kidney injury; VT, ventricular tachycardia; MACE, major adverse cardiac event; PCI, percutaneous coronary intervention; TVR, target vessel revascularization;
TLR, target lesion revascularization; MI, myocardial infarction; CABG, coronary artery bypass graft; NS, not significant.
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emia, endothelial disorders, and neuroendocrine disor-
ders, which are all important contributors to the further
advancement of RD in patients with ACS [4]. The
American Kidney Foundation guidelines state that the
prevalence of coronary heart disease increases with de-
creasing eGFR. A decrease in GFR to < 60 mL/min/
1.73 m2 is an independent risk factor for coronary heart
disease [16]. In this study, patients with more severe RD
had higher mortality after ACS and were more likely to
have hypertension, hyperlipidemia, ischemic heart dis-
ease, and cardiac dysfunction. Coronary angiography is
relatively contraindicated in these patients. Surgeons































Figure 1 Kaplan-Meier survival in elderly patients with ACS.communicate with patients and their families about the
risks of angiography. It is important to ensure adequate
hydration before and after coronary angiography, per-
form dialysis as needed, and prevent contrast-induced
nephropathy and further damage to renal function. Pa-
tients with more severe RD undergo less frequent coron-
ary angiography. Evaluation of renal function is an
important aspect of risk assessment in patients with
ACS. Current biomarkers of early changes in renal func-
tion include microalbuminuria and decreased eGFR [17].
Many patients become progressively malnourished as
renal function decreases. The resulting decreases in
albumin, prealbumin, and transferrin levels activate the
inflammatory cascade [18,19]. Several aspects of pro-
gressive renal failure cause changes in plasma compos-
ition and endothelial structure and function that favor
vascular injury [20-22]. However, the mechanisms un-
derlying the impact of RD on the prognosis after ACS
remain unclear. Significantly elevated serum levels of
interleukin-6, CRP, and tumor necrosis factor-α have been
observed in patients with renal failure, but no differences
in prognosis have been reported between patients who
underwent long-term dialysis and those who did not. In
patients with CKD, the prevalences of vascular disease
and malnutrition-inflammation-atherosclerosis syndrome
increase as renal function decreases. Comorbidities may
contribute to these changes [22,23]. Elevated inflammatory
Table 5 COX regression analysis on different renal
insufficiency and other risk factors
Factors Hazard ratio (95% CI) P
Mild RD (eGFR≧90 mL/min/1.73 m2) 1.000
Moderate RD
(30≦eGFR < 90 mL/min/1.73 m2)
0.892 (0.506 ~ 1.781) 0.393
Severe RD
(15≦eGFR < 30 mL/min/1.73 m2)
1.983 (1.014 ~ 5.543) 0.034
Renal failure
(eGFR < 15 mL/min/1.73 m2)
2.724 (1.051 ~ 6.955) 0.021
Hypertension 1.218 (0.371 ~ 3.995) 0.745
DM 1.971 (0.622 ~ 6.241) 0.249
Smoke 1.000 (0.975 ~ 1.026) 0.973
Sex 0.658 (0.229 ~ 1.894) 0.438
Hyperlipidemia 0.392 (0.060 ~ 2.564) 0.329
Stroke 0.161 (0.015 ~ 1.701) 0.129
Age 1.014 (0.958 ~ 1.073) 0.632
Anemia 0.113 (0.019 ~ 0.666) 0.016
Medications
Aspirin 1.083 (0.316 ~ 3.719) 0.899
Β-blocker 2.181 (0.734 ~ 6.479) 0.161
ACEI/ARB 1.871 (0.624 ~ 5.611) 0.264
CCB 1.255 (0.470 ~ 3.356) 0.650
Statins 0.258 (0.080 ~ 0.835) 0.024
ACEI: Angiotensin-converting enzyme inhibitors, ARB: Angiotensin II receptor
antagonists, CCB: Calcium channel blocker.
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diovascular disease [24,25]. The results of this study con-
firmed that severe RD is associated with high levels of
inflammatory cytokines such as hs-CRP, but the cytokine
levels were not independent predictors of MACE. Cys C is
an independent predictor of early RD [26]. Our results
also show higher Cys C levels in patients with more severe
RD. Severe anemia and RD were independent risk factors
for MACE, which is consistent with the results of previous
studies [27,28].
The term “renal senescence” refers to a series of
physiological and structural changes resulting in de-
creased renal function in aging individuals. Our findings
are consistent with earlier reports that healthy individ-
uals aged over 60 years have a GFR 20 to 30% lower
than in individuals aged less than 50 years. The percent-
age of globally sclerosed glomeruli is frequently 10 to
40% in 60-year-old patients [29,30], which results in
functional glomerulopenia. Sclerosis of the juxtamedul-
lary glomeruli of aging patients results in a vascular con-
nection between afferent and efferent arterioles that
maintains an adequate rate of medullary blood flow
while shunting blood past the obsolescent glomeruli.
Elderly patients often have high morbidity associated
with hypertension, diabetes mellitus, and other diseases,leading to the development of glomerular sclerosis. The
elderly are also prone to RD due to stress or adverse
drug effects, and such RD is difficult to reverse. Add-
itionally, the prevalences of coronary heart disease and
RD gradually increase with age. Evaluation of the risk
factors and long-term prognosis of elderly patients with
coronary heart disease and RD is therefore important.
Our findings confirmed that in patients with ACS, more
severe RD is associated with older age, hypertension,
hyperlipidemia, and poor cardiac function. During
follow-up, the incidence of MACE was significantly
higher in patients with severe RD than in patients with
mild RD. In patients with ACS, severe RD is an inde-
pendent predictor of MACE and is associated with poor
long-term prognosis. Evaluation of risk factors, overall
renal function, and treatment options is therefore very
important in patients with ACS.
This study has some limitations that should be dis-
cussed. First, the proportion of patients with unstable
angina is higher in this study than that of previously re-
ported studies. The American College of Cardiology/
American Heart Association guidelines suggest that ap-
proximately 37% of patients with ACS have unstable an-
gina [31]. We believe that the high proportion of
patients with unstable angina may be attributed to the
fact that the majority of patients were Beijing residents.
It would therefore be useful for these patients to attend
regular medical examinations, enabling earlier diagnosis
and treatment. Second, 19 patients were lost to follow-up.
Some of these patients lived in remote areas, with poor ac-
cess to transport and communication media. Some pa-
tients may also have relocated during the relatively long
follow-up period. Finally, patients with more severe RD
underwent coronary angiography less frequently. This
may be because RD is a relative contraindication to coron-
ary angiography. Acute deterioration in renal function due
to administration of contrast medium is a well-recognized
complication after coronary angiography, particularly in
patients with pre-existing CKD. We also considered these
procedures in the multivariate Cox analysis.
Conclusions
Among patients with ACS, severe RD was associated
with advanced age, diabetes, hypertension, and cardiac
dysfunction. Severe RD was an independent risk factor
for MACE, and was associated with poor prognosis.
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